QPPV.COM KNOWLEDGE ASSESSMENT

Empagliflozin: Discovery, Development, Safety and Pharmacovigilance

Test your understanding of the concepts covered by Empagliflozin: Discovery, Development, Safety and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 A patient taking empagliflozin has nausea, rapid breathing, ketones and metabolic acidosis, but only modestly elevated blood glucose. What is the most appropriate clinical and pharmacovigilance interpretation?
Question 2 of 10 A US surgical team asks about withholding empagliflozin before a procedure involving prolonged fasting. Which statement reflects the article’s jurisdiction-specific detail?
Question 3 of 10 Which statement correctly interprets the EMPA-REG OUTCOME population?
Question 4 of 10 When assessing pregnancy exposure, which approach best reflects the article’s advice?
Question 5 of 10 Why should results from EMPA-REG OUTCOME, EMPEROR-Reduced, EMPEROR-Preserved and EMPA-KIDNEY not be ranked as if they were direct head-to-head comparisons?
Question 6 of 10 How should a later follow-up of EMPA-KIDNEY be interpreted when considering longer-term benefit?
Question 7 of 10 Which interpretation best reflects the EMPA-KIDNEY findings and population?
Question 8 of 10 Which action is most consistent with effective QPPV oversight for a medicine used across diabetes, heart failure and CKD populations?
Question 9 of 10 What is the most accurate summary of the EMPEROR-Preserved evidence described in the article?
Question 10 of 10 A clinician observes that empagliflozin produces little glucose lowering in a patient with substantially reduced eGFR and concludes that cardiorenal benefit is therefore impossible. What is the most appropriate interpretation?

Select an answer to continue.

QPPV.com